Navigation Links
Antibodies for new rotavirus vaccines
Date:7/17/2012

CSIRO has been contracted by PATH (Program for Appropriate Technology in Health) to produce antibodies on a large scale that will aid the development of new, safe, affordable and effective vaccines against rotavirus, a major cause of severe and fatal diarrhoea in young children worldwide.

Rotavirus kills nearly half a million children every year, 85 per cent of whom live in developing countries. The virus is one of the most common causes of hospital and emergency admissions for children under five in Australia.

Since the introduction of two rotavirus vaccines, Rotarix and RotaTeq, to Australia's National Immunisation Program in 2007, hospitalisations of children under five years of age due to rotavirus gastroenteritis have been reduced by over 70 per cent.

PATH, an international not-for-profit organisation, is working to increase access to and effectiveness of existing commercial rotavirus vaccines worldwide, while also working with emerging-country vaccine manufacturers to speed up the development of safe, effective, and more affordable new rotavirus vaccines.

"CSIRO will produce a large quantity of antibodies specific to the strains of rotavirus that are in the vaccines our partners are developing, which will serve as important material for our project," said Dr Georges Thiry, director of PATH's rotavirus vaccine development project.

"New vaccines and suppliers will increase the availability of rotavirus vaccines and increase competition, which in turn will help make all of the rotavirus vaccines on the market more affordable and accessible to the world's most vulnerable children."

Dr George Lovrecz, group leader for CSIRO's protein production and fermentation group, is confident that CSIRO's expertise from the tissue culture and purification teams will deliver excellent results.

"We are proud to be assisting this groundbreaking project that is working to help save the lives of children in the world's poorest countries," he said.

CSIRO will use their recombinant protein production facility in Clayton, Victoria, for the large-scale production of the antibodies.

"This unique, state-of-the-art facility will allow us to produce enough antibodies to supply PATH's partners for the next five years," said Dr Lovrecz.

"We will be producing six antibodies that will be used to test the quality of the rotavirus vaccines being developed."

The antibodies, originally prepared by Dr Carl Kirkwood from the Murdoch Childrens Research Institute, will be used by PATH's manufacturing partners in China, Brazil, and India and by the United States' National Institutes of Health.


'/>"/>

Contact: Merrin Fabre
Merrin.Fabre@csiro.au
61-395-458-362
CSIRO Australia
Source:Eurekalert

Related medicine news :

1. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
2. Antibodies from rabbits reduce risks associated with
3. Antibodies reverse type 1 diabetes in new immunotherapy study
4. ACP Immunization Advisor app makes it easier for doctors to identify vaccines for patients
5. Control gene for conveyor belt cells could help improve oral vaccines, treat intestinal disease
6. OHSU Oregon National Primate Research Center develops new, safer method for making vaccines
7. World Health Assembly endorses new plan to increase global access to vaccines
8. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2016)... (PRWEB) , ... May 01, 2016 , ... ... http://www.womensexcellence.com that gives new mothers a better understanding of what to ... to call, · Adjusting to baby postpartum, · The blues and depression, · ...
(Date:4/30/2016)... ... April 30, 2016 , ... Create an abstract ... can distort and manipulate three-dimensional shapes with ease all within Apple Motion ... lines, polygons, polygon texture animation, opacity texture animation, overall shape texture displacement, twist, ...
(Date:4/30/2016)... (PRWEB) , ... April 30, ... ... by CBC News on April 4th, 2016 questioned the use of the ... to EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... In an ... mother and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent ... famous youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... JACKSONVILLE, Florida , April 28, 2016 ... in the development of innovative peptide and gene-based immunotherapeutics and ... announced it will be presenting at the 3rd Annual ... - 5 th , 2016 at Caesars Palace in Las ... at 8.00 am on Wednesday, May 4 th by ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... Elekta today announced that its ... the focal point of seven scientific presentations at ESTRO ... Radiotherapy & Oncology, taking place April 29 - May ... system and a high-field MRI scanner with sophisticated software ... anatomy in real time. The MR-linac is designed to ...
Breaking Medicine Technology: